References
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162–173
Akman-Demir G, Mutlu M, Kiyat-Atamer A, Shugaiv E, Kurtuncu M, Tugal-Tutkun I, Tuzun E, Eraksoy M, Bahar S (2015) Behçet’s disease patients with multiple sclerosis-like features: discriminative value of Barkhof criteria. Clin Exp Rheumatol 33:S80–S84
Çoban O, Bahar S, Akman-Demir G et al (1999) Masked assessment of MRI findings: is it possible to differentiate neuro-Behçet’s disease from other central nervous system diseases? Neuroradiology 41:255–260
Saruhan-Direskeneli G, Yentür SP, Mutlu M, Shugaiv E, Yesilot N, Kürtüncü M, Akman-Demir G (2013) Intrathecal oligoclonal IgG bands are infrequently found in neuro-Behçet’s disease. Clin Exp Rheumatol 31:25–27
Motomura S, Tabira T, Kuroiwa Y (1980) A clinical comparative study of multiple sclerosis and neuro-Behçet’s syndrome. J Neurol Neurosurg Psychiatry 43(3):210–213
Newman NJ, Lessell S, Winterkorn JM (1991) Optic chiasmal neuritis. Neurology 41:1203–1210
Kidd D (2011) The optic chiasm. Handb Clin Neurol 102:185–203
Aoyagi R, Sakai T, Kono Y et al (2013) A case of Behçet’s disease with development of MS-like lesions in the CNS and spinal cord. Clin Exp Rheumatol 31:154
Antonazzo IC, Raschi E, Vignatelli L, Baldin E, Riise T, D’Alessandro R, de Ponti F, Poluzzi E (2017) Occurrence of multiple sclerosis after drug exposure: insights from evidence mapping. Drug Saf 40:823–834
Gill C, Rouse S, Jacobson RD (2017) Neurological complications of therapeutic monoclonal antibodies: trends from oncology to rheumatology. Curr Neurol Neurosci Rep 17:75
Kemanetzoglou E, Andreadou E (2017) CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep 17:36
Massacesi L, Tramacere I, Amoroso S, Battaglia MA, Benedetti MD, Filippini G, la Mantia L, Repice A, Solari A, Tedeschi G, Milanese C (2014) Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One 9:e113371
Casetta I, Iuliano G, Filippini G (2007) Azathioprine for multiple sclerosis. Cochrane Database Syst Rev 17:CD003982
Messori A, Fadda V, Maratea D, Trippoli S (2014) Indirect meta-analytical comparison of azathioprine and of beta interferon effectiveness in all forms of multiple sclerosis pooled together. J Neurol Sci 347(15):408–410
Ticha V, Kalincik T, Havrdova E (2012) Interferon-β or azathioprine as add-on therapies in patients with active multiple sclerosis. Neurol Res 34:923–930
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Rights and permissions
About this article
Cite this article
Mantero, V., Rigamonti, A., Fiumani, A. et al. Neurobehçet, multiple sclerosis or overlap syndrome? A case report. Neurol Sci 39, 1625–1627 (2018). https://doi.org/10.1007/s10072-018-3420-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-018-3420-4